Anthropic PBC has launched a new artificial intelligence platform specifically engineered to assist researchers in automating scientific work, targeting the time-consuming and repetitive elements that consume much of scientists' daily schedules. Claude Science, rolled out on June 30, represents a significant expansion of the company's ambitions beyond general-purpose AI into specialised professional domains, with particular emphasis on accelerating discoveries in biology and chemistry research.
The platform consolidates access to more than 60 scientific databases and research tools that scientists typically consult separately, enabling researchers to pose questions in plain English and receive integrated answers without manually querying multiple sources. By automating multistep research tasks—including protein structure prediction and molecular modelling—Claude Science aims to free researchers from routine computational work and redirect their efforts toward higher-level scientific inquiry and interpretation. The system's design reflects a growing recognition within the AI industry that general-purpose models require substantial customisation to deliver genuine utility in technical fields where precision and traceability matter profoundly.
Anthropologic is offering Claude Science as a beta release exclusively to its subscription-paying users, a strategy that allows the company to gather real-world performance data while maintaining premium positioning. This tiered approach also generates recurring revenue from a professional user base willing to pay for productivity gains. The announcement occurred at a San Francisco event featuring prominent figures from the pharmaceutical sector, including Dario Amodei, Anthropic's chief executive, alongside Vas Narasimhan, chief executive of Novartis AG and an Anthropic board member, and Bristol-Myers Squibb CEO Chris Boerner—a lineup that underscores the company's deliberate cultivation of pharmaceutical industry relationships.
Beyond releasing software tools, Anthropic has disclosed that it is now pursuing its own internal preclinical drug discovery programs. According to Eric Kauderer-Abrams, Anthropic's head of life sciences, the company intends to focus on therapeutic areas that the traditional pharmaceutical and biotech sectors have historically dismissed as commercially unviable or too scientifically challenging. This vertical integration strategy—combining AI tooling with proprietary drug research—positions Anthropic not merely as a technology vendor but as a direct competitor in the pharmaceutical value chain, a move that carries profound implications for how established drug manufacturers might view the company's commercial intentions.
Anthropic's aggressive expansion into professional services automation reflects intense competition with OpenAI and other AI developers to justify extraordinarily high valuations and establish durable revenue streams. The company, currently valued at US$965 billion (RM3.94 trillion), has signalled plans to pursue an initial public offering as early as autumn, making the demonstration of revenue-generating applications increasingly urgent. Throughout the past year, Anthropic and OpenAI have systematically introduced tools targeting financial services, legal work, healthcare, and scientific research—essentially mapping the knowledge economy's highest-value sectors and developing AI solutions for each.
Anthropic's recent moves have demonstrably unsettled financial markets, reflecting broader anxieties about technological displacement across professional services. In February, the company launched Claude Cowork to automate certain legal functions such as contract review and legal memoranda, a development that markets perceived as sufficiently threatening to trigger a US$1 trillion (RM4.08 trillion) sell-off in equity markets. The pattern suggests that each new professional application announcement carries market-moving implications, with investors reassessing which service sectors face disruption and whether current valuations adequately reflect the timeline and magnitude of potential revenue cannibalization.
Amodei has articulated an ambitious vision of using AI to accelerate drug discovery, suggesting that over the coming year the company hopes to demonstrate meaningful progress in identifying novel therapeutic targets. His framing implies that Anthropic recognises a credibility gap between technological capability demonstrations and commercially validated outcomes in high-stakes domains like pharmaceutical development. The implicit acknowledgement—that bold proclamations about AI capabilities must eventually be backed by tangible results—reflects pressure both from investors seeking validation of extraordinary valuations and from prospective enterprise clients demanding evidence before committing to large-scale deployments.
Vas Narasimhan's remarks at the event highlighted an emerging tension within the AI-enabled pharmaceutical sector: the simultaneous desire to advance innovation whilst establishing appropriate regulatory guardrails before catastrophic failures force reactive governance. His observation that waiting for a crisis to trigger regulation represents a suboptimal policy outcome suggests that responsible pharmaceutical industry leadership recognises the need for proactive engagement with regulators. This positioning also signals to governments and legislators that leading industry figures favour constructive regulatory dialogue over adversarial standoffs, a diplomatic stance that may facilitate smoother integration of AI systems into drug discovery pipelines across the Asia-Pacific region and globally.
Claude Science employs Anthropic's established Claude models, including Opus 4.8 released in May, but implements crucial verification mechanisms specifically designed for scientific applications. The platform generates outputs accompanied by traceable details that enable scientists to validate information accuracy, whilst any images produced by the system include documentation of the methodology used in their generation. This emphasis on transparency and reproducibility reflects fundamental scientific principles and addresses legitimate concerns about deploying black-box AI systems in contexts where experimental validity and peer review require clear audit trails.
The timing of Claude Science's launch occurs against a backdrop of intensifying geopolitical tensions surrounding advanced AI technology. Anthropic recently disabled access to its most sophisticated models—Fable 5 and Mythos 5—in response to Trump administration directives aimed at restricting foreign access to advanced capabilities. This restriction reflected U.S. government concerns about potential national security implications of diffusing cutting-edge AI systems internationally. Subsequently, on June 26, Anthropic secured governmental approval to restore some access to Mythos 5 after addressing concerns about technological proliferation risks, though no announcement has been made regarding restrictions on the Fable 5 model.
For Malaysian and Southeast Asian stakeholders, Anthropic's evolution into a pharmaceutical AI developer and the broader deployment of AI across professional services carries substantial implications. The region's growing biotech sector and pharmaceutical manufacturing ecosystem may benefit from access to advanced research automation tools, potentially accelerating discovery timelines and reducing costs for regional drug developers. However, the geopolitical dimensions of AI technology—including export controls and access restrictions—may limit which institutions and companies in the region can fully utilise cutting-edge systems. Additionally, the demonstrated capacity of AI to automate professional knowledge work raises urgent questions about workforce development, educational curricula, and whether regional institutions are adequately preparing their populations for labour markets where AI-augmented productivity becomes standard across prestigious professions.
